重组人生长激素治疗肝硬化低蛋白血症对比疗效分析
肝硬化,,生长激素；人血白蛋白；肝硬化；低蛋白血症,1资料与方法,2结果,3讨论,参考文献
摘 要 为探讨重组人生长激素对肝硬化低蛋白血症的临床治疗作用及特点，将54例血清白蛋白含量低于35 g·L-1的肝硬化低蛋白血症患者随机分为3组：重组人生长激素治疗组(A)给予重组人生长激素4 IU，肌注，1次/2日，疗程30 d，人血白蛋白治疗组(B)给予20%人血白蛋白100 g，静滴，2次/周，疗程30 d，两组给予相同保肝、对症药物治疗方案，对照组(C)只给予相同方案的保肝、对症治疗药物。分别于开始治疗后15、30、60、90 d测定各项观察指标。治疗后15天白蛋白治疗组血清白蛋白含量上升(P<005)，30 d时3组患者血清白蛋白含量均上升(P<0.05)，两组治疗组上升更明显；60 d后生长激素治疗组血清白蛋白水平升至高点水平，白蛋白治疗组及对照组较前降低，组间差异显著(P<0.01)；90 d后生长激素治疗组血清白蛋白含量仍维持高点水平，且肝功能好转，而白蛋白治疗组及对照组降至治疗前水平，提示重组人生长激素可明显提高肝硬化低蛋白血症患者血清白蛋白水平，改善肝功能，中远期疗效好。关键词 生长激素；人血白蛋白；肝硬化；低蛋白血症
Effect of recombinant human growth hormone in the treatment of liver cirrhosis with hypoproteinemia
Abstract Objective:To investigate the effect of human growth hormone in the treatment of liver cirrhosis with hypoproteinemia. Methods:Fiftyfour patients with liver cirrhosis,whose albumin level was below 35 g·L-1,were randomly divided into three groups: recombinant human growth hormone treatment group(Group A), albumin treatment group(Gruop B) and control group.Contents of albumin,ALT and other items were measured 15,30,60 and 90 day after the treatments. Results: An increase in plasma albumin content was observed in groupB 15 days after the treatment(P<0.05), and in all groups 30 days after(P<0.05),but the change in the control group was not so significant as that in both treatment groups. 60 days after the treatments,the plasma albumin in Group A reached the peak level,but it dropped in group B and the control group (P<0.01).90 days after the treatments,the plasma albumin remained at a higher level in Group A but dropped to the level as before treatments in Group B and the control group. Conclusion: This results showed that the recombinant human growth hormone can increase the level of albumin and improve the liver function in patients with liver cirrhosis with a longterm curative effect. ......
您现在查看是摘要页，全文长 7054 字符。